Melasma — a patient-decision guide
Melasma is a chronic, recurrent pattern of facial pigmentation more common in women than men, driven by a combination of hormonal and ultraviolet factors. The honest framing for any melasma conversation is control rather than cure: treatment can substantially fade visible patches and slow recurrence, but the underlying tendency remains. This guide explains what melasma is biologically, what triggers it, what evidence-based management looks like, why Indian-skin Fitzpatrick III–VI considerations sit centrally in the framework, and how the consultation actually approaches the conversation.
What this guide does and does not do
This guide explains melasma at the principles level: the chronic-recurrent biology, the hormonal-and-photo driver mix, the layered evidence-based framework (sun-protection foundation, topical agents, procedural support where appropriate, lifestyle and trigger management), the specific cautions around hydroquinone and laser work, and the Indian-skin parameter calibration that sits centrally for darker skin types.
The guide does not provide a diagnosis or prescribe specific topical or systemic agents. Hydroquinone, tranexamic acid (topical or oral), and procedural pathways are dermatologist-prescribed under appropriate guidelines and individualised assessment. The framework explicitly does not endorse informal "lightening" products, which carry meaningful risk in Indian skin including the paradoxical pigmentation patterns the guide describes. For specific questions, a dermatologist consultation is the right next step.
What melasma actually is
Melasma is over-active melanocyte response to a combination of hormonal and ultraviolet stimuli, producing patchy hyperpigmentation in characteristic distribution. The visible pattern is typically symmetrical and concentrated across the cheeks, forehead, upper lip, and bridge of the nose; less commonly the chin and jawline. The colour ranges from light tan through brown to grey-brown depending on depth (epidermal versus dermal versus mixed) and duration. Three depth patterns are recognised clinically: epidermal melasma (superficial pigment, more responsive to topical work), dermal melasma (deeper pigment, less responsive), and mixed-pattern melasma (most common, requires layered approach). Wood's lamp examination at consultation can support depth assessment; treatment-response varies meaningfully by depth.
Melasma is far more common in women than men — estimates suggest the female-to-male ratio is roughly nine-to-one, reflecting the hormonal driver. It frequently begins or flares during pregnancy ("the mask of pregnancy"), with oral contraceptive use, or with hormone replacement therapy. Indian and broader Fitzpatrick III–VI skin shows substantially higher prevalence and persistence than lighter Fitzpatrick types. Family pattern matters; melasma runs strongly in families, and genetic predisposition is one of the inputs the dermatologist weighs at assessment.
The hormonal-and-photo driver mix
Melasma reflects multiple drivers acting together. Hormonal modulation is central — pregnancy, oral contraceptive use, hormone replacement therapy, and perimenopausal shifts all influence melasma activity. Many patients can identify a specific hormonal trigger that started or flared their picture. Ultraviolet exposure is the largest single trigger of visible patches; even brief sun exposure on melasma-prone skin produces visible darkening that takes weeks-to-months to settle. Visible light (including indoor near-window exposure and screen exposure to a lesser degree) also contributes; broad-spectrum sun-protection that includes visible-light coverage matters more for melasma than for some other pigmentation conditions.
Heat exposure flares melasma in many patients independent of ultraviolet — sauna, intense exercise, hot showers, occupational heat exposure (cooking, hot kitchens) all activate melanocytes. Genetic predisposition is significant. Once melasma is established, multiple drivers can keep it active, which is why management is layered rather than single-pathway. Identifying the personal trigger pattern — the specific drivers most active in the individual case — supports both treatment design and long-term control.
Control, not cure — the framing
The honest framing for melasma is control. Treatment can substantially fade visible patches and slow recurrence, but the underlying melanocyte tendency remains. Discontinuing sustained sun-protection or topical maintenance, hormonal shifts, or new triggers commonly bring the patches back. This is not failure; it is the biology. Patients who arrive expecting cure-and-done often experience disappointment when the picture recurs after stopping treatment; patients who arrive understanding the chronic-management framing consistently report better long-term experience because their expectations match the underlying condition.
Treatment plans are designed for the long term. An initial intensive phase fades the visible patches; a maintenance phase sustains the result with reduced topical intensity, sustained sun-protection, and trigger awareness. The maintenance phase often runs indefinitely. Periodic flares are managed with brief intensification of topical regimens. The dermatologist reviews and adjusts across life stages as hormonal context shifts, sun-exposure changes, and patient priorities evolve.
The layered evidence-based framework
Disciplined sun-protection is the foundation — broad-spectrum (UVA and UVB), generous (most patients use less than the protective amount), reapplied through the day, including indoor near-window exposure where windows admit ultraviolet, and ideally with visible-light coverage for melasma-specific protection. Sun-protection alone produces some fading in many cases; sun-protection without other layers underperforms substantially less than other layers without sun-protection. The framework treats sun-protection as non-negotiable rather than optional.
Topical agents form the second layer. Hydroquinone (typically 2–4% under dermatologist supervision) is one of the most evidence-supported agents but requires defined-duration use with planned breaks to avoid the paradoxical ochronosis that long-term continuous use can produce. Tranexamic acid (topical and, in selected patients, oral) has accumulated meaningful evidence as a melasma-specific agent. Azelaic acid combines anti-pigment and anti-inflammatory action. Kojic acid, niacinamide, vitamin C, and certain newer agents have supportive roles. Combinations the dermatologist tailors typically outperform single-agent regimens.
Procedural pathways have a role under careful calibration. Chemical peels at appropriate concentrations support pigment-cell turnover; selection between superficial and medium-depth peels is calibrated for Indian-skin safety. Q-switched lasers, picosecond lasers, and selected fractional platforms have evidence under conservative parameters; aggressive parameters can paradoxically flare melasma. Procedural work runs alongside the topical and sun-protection layers rather than as a substitute. Combination outperforms any modality alone.
Hydroquinone — careful use
Hydroquinone is one of the most evidence-supported topical agents for melasma, but carries specific considerations that distinguish it from routine cosmetic actives. Long-term continuous use (months running into years) can produce ochronosis — a paradoxical darker, often blue-grey discolouration that is itself difficult to reverse. The framework uses hydroquinone in defined-duration intensive phases (typically a few months on, then a planned break with non-hydroquinone maintenance), at appropriate concentrations, and under dermatologist supervision rather than as an indefinite over-the-counter default.
Patients who use informal hydroquinone-containing products from unsupervised channels indefinitely sometimes develop ochronosis or other adverse outcomes that are themselves harder to manage than the original melasma. The dermatologist screens for prior informal hydroquinone use at consultation and adjusts the plan accordingly. Patients with established ochronosis need a different framework than the standard melasma course; treatment for ochronosis is its own conversation.
Indian-skin Fitzpatrick III–VI framing
Melasma in Indian skin requires careful parameter calibration across all modalities. Aggressive topical sequencing produces additional inflammation that paradoxically worsens melasma. Aggressive procedural parameters in darker skin can produce post-inflammatory hyperpigmentation that compounds the original picture. The framework leans deliberately conservative — gentler topical introduction with gradual escalation, longer between-session intervals for procedural work, conservative parameter selection, sustained barrier-and-sun-protection support throughout. Under-treatment is consistently a safer default than over-treatment for Indian-skin melasma.
The trade-off matters: aggressive treatment that initially fades melasma can leave a worse picture than the starting point if it produces post-inflammatory pigmentation or paradoxical melasma flare. Conservative parameter selection extends the course in months but produces more durable, lower-risk fade in the long run. The Indian Skin Treatment Safety Guide describes the broader framework. The pigmentation in Indian skin guide covers the broader Indian-skin pigmentation conversation.
What worsens melasma
Several common patterns worsen melasma. Continued unprotected ultraviolet exposure is the largest single factor — even with the best topical regimen, melasma without sun-protection underperforms. Heat exposure flares melasma in many patients; saunas, intense exercise, hot showers, and occupational heat all contribute. Hormonal changes — pregnancy, contraceptive starts, perimenopausal shifts — flare or trigger melasma. Aggressive topical actives stacked too quickly produce irritation that drives melanocyte activity. Harsh scrubs, aggressive peels at inappropriate parameters, and procedural work pushed too far in darker skin all complicate melasma. Informal "lightening" creams containing unregulated steroids produce paradoxical flare with rebound pigmentation when stopped — a particularly difficult pattern to manage. Identifying and modifying triggers is part of the long-term plan.
When to consult a dermatologist
Reasonable triggers for melasma consultation include: characterised pigmentation patches matching melasma distribution; pigmentation that started during pregnancy, with contraceptive use, or in perimenopause; persistent dark patches that have not responded to over-the-counter regimens; flare or worsening of pigmentation despite topical work; prior use of informal "lightening" products with concerns about long-term effect; or simply the patient's decision to address persistent melasma rather than continuing to chase OTC products. Booking a dermatologist consultation is the appropriate first step.
Practical next steps
Several practical steps support a useful melasma consultation. Photograph the affected zones in identical lighting across multiple days — melasma intensity varies and the captured baseline is useful. List all current skincare honestly, including any informal "lightening" products that have been used, current or past — this disclosure matters meaningfully for the clinical plan. Note hormonal history including pregnancies, contraceptive use, and current cycle or menopausal status. Note family pattern of melasma if known. Begin disciplined sun-protection now if not already a habit; even a few weeks of consistent sun-protection produces visible change in some patients. Pause aggressive new actives in the weeks before the appointment so the dermatologist sees the actual baseline.
Safety, expectation, and honest framing
Melasma treatment carries the considerations relevant to each pathway. Hydroquinone over extended use carries paradoxical-pigmentation risk. Topical retinoids and other actives can produce irritation, photosensitivity, and pigment outcomes if pushed without barrier support. Procedural laser and peel work in Indian skin carries post-inflammatory hyperpigmentation risk that runs higher than in lighter skin. Oral tranexamic acid carries clotting-related considerations and contraindications. No specific clearance percentages, complete-resolution promises, or fixed-transformation commitments are offered by the clinic. Calibrated expectations against the chronic-recurrent biology produce the most useful experience. Long-term sun-protection and trigger management determine the durability of any improvement more than any single procedural intervention.
Related pages and next reading
Frequently asked questions
What is melasma?
Melasma is a chronic, recurrent pattern of facial hyperpigmentation that produces patchy, often symmetrical brown or grey-brown patches across the cheeks, forehead, upper lip, and bridge of the nose. It reflects over-active melanocyte response to a combination of hormonal and ultraviolet drivers, and is far more common in women than men. The honest framing is that melasma is a tendency that is managed and controlled rather than cured — visible improvement is realistic, but the underlying tendency remains and durable management depends on sustained sun-protection and trigger awareness.
Is melasma the same as other dark patches?
No. Melasma is one specific pigmentation pattern with characteristic distribution, hormonal-and-photo driver mix, and chronic-recurrent behaviour. Other patterns of facial pigmentation — sun-induced lentigines, post-inflammatory hyperpigmentation, drug-induced pigmentation, periorbital pigmentation, freckles — have different drivers and respond differently. The dermatologist separates these at consultation because pattern identification determines the management pathway. Patients arriving assuming "all dark patches are melasma" sometimes pursue inappropriate treatments. The broader framework is in the hyperpigmentation guide.
What triggers melasma?
Melasma is multi-factorial. Hormonal context drives it meaningfully — pregnancy ("the mask of pregnancy"), oral contraceptive use, hormone replacement therapy, perimenopausal shifts, and broader hormonal modulation all contribute. Ultraviolet exposure is the largest single trigger; visible light (including indoor near-window exposure and screen blue light to a lesser degree) also contributes. Heat exposure can flare melasma. Genetic predisposition is significant — melasma runs in families. Skin type matters; melasma is more common and more persistent in Fitzpatrick III–VI skin. Identifying the personal trigger pattern at consultation supports better long-term control.
Can melasma be cured?
No. The honest framing is control rather than cure. Melasma is a chronic tendency that produces visible patches when triggers are active — sun exposure, hormonal shifts, heat, irritation. Treatment can substantially fade visible patches and slow recurrence, but the underlying melanocyte tendency remains. Discontinuing sustained sun-protection or topical maintenance, or experiencing hormonal changes, frequently brings the patches back. The framework treats melasma as a long-term-management conversation rather than a one-course-and-done treatment.
What treatments are evidence-based for melasma?
Several layers form the framework. Disciplined sun-protection is the foundation — broad-spectrum, generous, reapplied, including indoor and near-window exposure; melasma without sun-protection underperforms regardless of other interventions. Topical agents include hydroquinone (in appropriate concentrations and durations under dermatologist guidance), tranexamic acid (topical and oral), azelaic acid, kojic acid, niacinamide, and combinations the dermatologist tailors. Procedural pathways including chemical peels and certain laser modalities have a role with careful Indian-skin parameter calibration. Combinations consistently outperform single-modality approaches.
Why is hydroquinone managed carefully?
Hydroquinone is one of the most evidence-supported topical agents for melasma but carries specific use considerations. Long-term continuous use can paradoxically produce ochronosis — a darker, often blue-grey discolouration that is itself difficult to reverse. Appropriate use is at calibrated concentrations for defined durations, often with planned breaks, and under dermatologist supervision. Patients who use over-the-counter hydroquinone-containing products indefinitely without supervision sometimes develop ochronosis or other adverse outcomes. The framework here uses hydroquinone where indicated under specific guidelines, not as an indefinite default.
What about oral tranexamic acid for melasma?
Oral tranexamic acid has accumulated meaningful evidence for melasma support in selected patients. It is dermatologist-prescribed, carries specific contraindications (clotting risk, certain medical histories), and requires appropriate patient selection and monitoring. It is not a default first-line and is not appropriate for every patient. Where appropriate, it can support melasma response alongside topical and procedural work. The framework here is principles-only; the prescribing decision is individualised at consultation.
How does melasma respond to laser?
Laser modalities have a complex relationship with melasma. Some laser approaches help; others can paradoxically worsen melasma by triggering melanocyte activity. Q-switched lasers, picosecond lasers, and certain fractional approaches have a role under careful Indian-skin parameter calibration, but inappropriate selection or aggressive parameters can flare the condition. The framework calibrated for Indian skin emphasises conservative parameters, longer between-session intervals, and combination with topical and sun-protection layers rather than laser as standalone. Patients with worsening melasma after prior laser elsewhere benefit from re-examination and reset of the framework.
Why does Indian-skin context matter so much for melasma?
Melasma is more common, more persistent, and more challenging to manage in Fitzpatrick III–VI skin than in lighter Fitzpatrick types. Aggressive treatments calibrated for lighter skin can paradoxically worsen melasma in Indian skin or produce post-inflammatory hyperpigmentation that complicates the original picture. The framework calibrated for Indian skin uses gentler topical sequencing, longer between-session intervals for procedural work, conservative parameter selection, and substantial sun-protection layers. Under-treatment is consistently a safer default than over-treatment for Indian-skin melasma. The Indian Skin Treatment Safety Guide covers the broader framework.
What worsens melasma?
Several common patterns worsen or trigger melasma flares. Continued unprotected ultraviolet exposure is the largest single worsening factor. Heat exposure — sauna, intense exercise, hot showers, summer cooking heat — flares melasma in many patients. Hormonal changes (pregnancy, contraceptive starts, perimenopausal shifts) can flare. Aggressive topical actives stacked too quickly, irritation from harsh scrubs or harsh procedures, and post-inflammatory pigmentation from any cause all complicate melasma. Informal "lightening" creams with unregulated steroids commonly produce paradoxical flare with rebound pigmentation when stopped.
How does melasma evolve through life?
Melasma trajectory varies. Many patients see substantial fluctuation — quieter winters, brighter summers; worse during pregnancy, settling post-partum; sometimes settling post-menopause as hormonal drivers shift. Some patients experience persistent activity across decades; others see the condition fade in mid-life. The framework treats melasma management as adjusted across life stages rather than a fixed protocol — the dermatologist reviews the plan as hormonal context shifts, sun-exposure changes, and the patient's priorities evolve.
What does a melasma consultation cover?
A useful consultation includes detailed history (onset, hormonal context, pregnancy and contraceptive history, family pattern, prior treatments and their effect including any informal "lightening" products), examination under appropriate light including Wood's lamp where useful for depth assessment, skin-type categorisation, and trigger-pattern review (sun exposure habits, heat exposure, occupational context). The dermatologist proposes a layered plan typically combining topical, procedural where appropriate, and lifestyle (sun-protection, trigger avoidance) layers, with realistic timeline framing.
Practical steps before a melasma consultation
Photograph the affected zones in identical lighting on multiple days — melasma intensity varies substantially. List all current skincare and any informal "lightening" products honestly; many patients have used products that need disclosure for clinical context. Note hormonal history (pregnancies, contraceptive use, current cycle status). Begin disciplined daily sun-protection now if not already a habit. Pause aggressive new actives in the two-to-four weeks before the appointment. Bring family-history information about melasma if known.
Is this guide medical advice?
No. This guide provides educational content about melasma at the principles level. Decisions about prescription topicals (hydroquinone, oral tranexamic acid), procedural laser work, and hormonal-context management are dermatologist-led. The Medical Disclaimer describes scope and limits.
Book a dermatologist consultation
If melasma or melasma-pattern pigmentation is the concern, the right next step is a dermatologist consultation where the picture can be assessed and a long-term management plan structured around your specific drivers and skin type.